Takeda concludes sale of select OTC and non-core assets to Hypera Pharma EP News Bureau Jan 31, 2021 This divestment agreement was first announced in March 2020
Takeda to divest select assets in China to Hasten Biopharmaceutic for $322 mn EP News Bureau Dec 21, 2020 The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China
